Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Teri Garner who wrote (28777)	12/16/1998 10:04:00 AM
From: Panita	Respond to of 119973

FOTO losing steam now after hitting 6 7/16

To: Teri Garner who wrote (28777)	12/16/1998 10:14:00 AM
From: MoneyMade	Read Replies (3) \| Respond to of 119973

FOTO---R O F L M A O!! giving away free scans???? M$ney

To: Teri Garner who wrote (28777)	12/16/1998 10:34:00 AM
From: Nescom	Read Replies (1) \| Respond to of 119973

NMPS News out PRECLINICAL STUDY SHOWS MATRITECH'S NMP179(TM) TEST 100% SENSITIVE IN tagged for: NMPS NMPS retrieval keys: !business !energy !european+community !foreign+business !global+news !international !public+companies !wall+street !western+europe biology business cancer corporate disease europe fda health japan market massachusetts nasdaq nuclear otc pharmaceuticals physicians pipeline prn product+development products sales securities technology trial united+states usa women Identifying Cervical Cancer Data To Be Presented At Annual Meeting Of The American Society for Cell Biology (ASCB) NEWTON, Mass., Dec. 16 /PRNewswire/ -- NMP179(TM), a diagnostic test being developed by Matritech, Inc. (Nasdaq: NMPS), has been shown in a preclinical study to be 100 percent sensitive in detecting cancer in cervical tissues, having detected 7 out of 7 cancer specimens. The study's results will be presented today at the annual meeting of the American Society for Cell Biology (ASBC) in San Francisco. "Cervical cancer is one of the most serious malignancies in women and frequently has fatal consequences if not discovered in early stages," said Ying-Jye Wu, Ph.D., Matritech's Vice President of Product Development and one of the authors of the NMP179 study. "We believe that NMP179 could clinically be a useful immunohistochemical marker for cervical cancer. These data are consistent with our previously reported preclinical trial results and we believe that NMP179 will be a very useful tool for physicians involved in the identification and management of cervical cancer patients." According to the International Federation of Gynecology and Obstetrics (FIGO), only 51 percent of women are diagnosed with cervical cancer in the early stages of the disease, when the rate of survival is 91 percent. The survival rate drops significantly -- to between 12 and 52 percent -- when cervical cancer remains undetected until later stages. Matritech, Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein (NMP) technology, discovered at the Massachusetts Institute of Technology and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast and prostate cancers. Matritech's nuclear matrix protein (NMP) technology platform correlates levels of NMPs in body fluids and tissues to the presence of cancer. Multiple published clinical studies have validated this ability of NMPs to detect early-stage cancerous abnormalities. Matritech has a deep pipeline of NMP-based products in pre-clinical and clinical development. The NMP22(R) Test Kit is approved in the United States, Europe and Japan for the management of patients with transitional cell carcinoma of the urinary tract (TCC/UT). It is the only approved kit for bladder cancer screening in Japan. Statement Under the Private Securities Litigation Reform Act Any forward looking statements related to the Company's expectations regarding the performance, cost, benefits, market acceptance, future sales and regulatory approvals of the Company's existing and future products are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include, but are not limited to, risks related to full-scale clinical trials, incorrect use of products by customers, unforeseen delays in or denials of FDA and other regulatory approvals, future product demand and pricing, performance of distributors, competitive products and technical developments, health care reform and general business and economic conditions. There can be no assurances that the Company's expectations for its products will be achieved. SOURCE Matritech, Inc -0- 12/16/98 /CONTACT: Stephen D. Chubb, CEO or David L. Corbet, President of Matritech, Inc., 617-928-0820 or Derek Caldwell of Sunrise Financial Group, 212-421-1616 or Steve Danehy, Associate or Jon Siegal, Associate of Ronald Trahan Associates, Inc., 617-332-0101/ (NMPS) CO: Matritech, Inc ST: Massachusetts IN: MTC SU: